Table 1 Characteristics of Participants Who Received any Dose of XBB.1.5- containing COVID-19 mRNA Vaccine from September 11, 2023 to June 1, 2024 by Vaccine Brand in N3C

244,494(100)

141,495 (57.9)

102,999 (42.1)

< 0.001

Age (mean (SD))

61.14 (16.93)

61.95 (16.72)

60.03 (17.16)

< 0.001

Age group, n (%)

–

–

–

< 0.001

18–40

36,075 (14.8)

18,988 (13.4)

17,087 (16.6)

–

41–60

64,921 (26.6)

36,993 (26.1)

27,928 (27.1)

–

61–80

118,686 (48.5)

69,879 (49.4)

48,807 (47.4)

–

≥ 80

24,812 (10.1)

15,635 (11.0)

9177 (8.9)

–

Sex, n (%)

–

–

–

0.022

Male

99,361 (40.6)

57,615 (40.7)

41,746 (40.5)

–

Female

145,133 (59.4)

83,880 (59.3)

61,253 (59.5)

–

Race, n (%)

–

–

–

< 0.001

White

177,411 (72.6)

99,650 (70.4)

77,761 (75.5)

–

Black

37,999 (15.5)

26,369 (18.6)

11,630 (11.3)

–

Asian

10,106 (4.1)

5759 (4.1)

4347 (4.2)

–

American Indian or Alaska Native

2617 (1.1)

1718 (1.2)

899 (0.9)

–

Native Hawaiian or Other Pacific Islander

399 (0.2)

125 (0.1)

274 (0.3)

–

Other

15,962 (6.5)

7874 (5.6)

8088 (7.9)

–

Ethnicity, n (%)

–

–

–

< 0.001

Hispanic or Latino

22,842 (9.3)

12,273 (8.7)

10,569 (10.3)

–

Not Hispanic or Latino

212,920 (87.1)

124,788 (88.2)

88,132 (85.6)

–

Other

8732 (3.6)

4434 (3.1)

4298 (4.2)

–

Comorbidity, n (%)

–

–

–

–

Hypertension

140,737 (57.6)

85,467 (60.4)

55,270 (53.7)

< 0.001

Diabetes mellitus

38,480 (15.7)

24,589 (17.4)

13,891 (13.5)

< 0.001

Heart failure

29,709 (12.2)

18,910 (13.4)

10,799 (10.5)

< 0.001

Cardiovascular disease

95,344 (39.0)

57,644 (40.7)

37,700 (36.6)

< 0.001

Obesity

76,094 (31.1)

46,701 (33.0)

29,393 (28.5)

< 0.001

Cancer

69,425 (28.4)

40,468 (28.6)

28,957 (28.1)

< 0.001

Cerebrovascular disease

17,014 (7.0)

10,564 (7.5)

6450 (6.3)

< 0.001